Want to see PTKFY full AI Analyst Report?
PTKFY Stock Chart & Stats
$7.76
$0.00(0.00%)
At close: 4:00 PM EDT
$7.76
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$7.32 - $16.02
Previous CloseN/A
Volume159.00
Average Volume (3M)35.00
Market Cap
$2.00B
Enterprise Value$1.78K
Total Cash (Recent Filing)$5.01T
Total Debt (Recent Filing)$829.84B
Price to Earnings (P/E)9.5
Beta0.58
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.33%
Share Statistics
EPS (TTM)16084.00
Shares Outstanding234,066,960
10 Day Avg. Volume0
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)2.19
Price to Sales (P/S)1.45
P/FCF Ratio20.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low leverage and attractive ROE provide durable financial flexibility. This strengthens resilience to economic shocks, supports steady dividend capacity, funds R&D/capex without reliance on debt, and preserves optionality for M&A or strategic investments over the medium term.
Diversified Healthcare Portfolio And DistributionMultiple business divisions and a nationwide distribution network reduce concentration risk and create cross-selling scale. Durable demand across prescription, OTC, and nutrition smooths revenue cycles and monetizes logistics capabilities for steady, resilient cash generation.
Steady Revenue Growth With Resilient MarginsMulti-year positive top-line growth and healthy margins underpin recurring profitability and FCF generation. While margins have eased from earlier highs, current margin profile still supports reinvestment into brands, manufacturing efficiency and distribution enhancements over the coming months.
Bears Say
Margin Compression TrendGradual erosion of gross and net margins suggests pricing pressure, rising input costs or mix shifts. If sustained, this can reduce cash available for R&D, marketing and dividends, compress returns on capital and make it harder to finance growth without margin-restoring actions.
Operating Cash Flow Volatility And Conversion RiskFree cash flow exists but operating cash flow trails EBIT and swings materially. Inconsistent OCF reduces predictability for capital allocation, may constrain sustained capex or acquisitions, and raises execution risk for longer-term investments and shareholder distributions.
Modest Medium-term Growth TrajectoryModerate top-line growth and limited EPS expansion mean slower scale-up of high-return initiatives versus faster-growing peers. This may limit margin expansion, reduce pricing power over time, and make securing market share gains more dependent on investment intensity and execution.
PT Kalbe Farma Tbk News
PTKFY FAQ
What was PT Kalbe Farma Tbk’s price range in the past 12 months?
PT Kalbe Farma Tbk lowest stock price was $7.32 and its highest was $16.02 in the past 12 months.
What is PT Kalbe Farma Tbk’s market cap?
PT Kalbe Farma Tbk’s market cap is $2.00B.
When is PT Kalbe Farma Tbk’s upcoming earnings report date?
PT Kalbe Farma Tbk’s upcoming earnings report date is Nov 03, 2026 which is in 44 days.
How were PT Kalbe Farma Tbk’s earnings last quarter?
PT Kalbe Farma Tbk released its earnings results on Jul 31, 2026. The company reported $0.223 earnings per share for the quarter.
Is PT Kalbe Farma Tbk overvalued?
According to Wall Street analysts PT Kalbe Farma Tbk’s price is currently Overvalued.
Does PT Kalbe Farma Tbk pay dividends?
PT Kalbe Farma Tbk pays a Annually dividend of $0.223 which represents an annual dividend yield of 2.33%. See more information on PT Kalbe Farma Tbk dividends here
What is PT Kalbe Farma Tbk’s EPS estimate?
PT Kalbe Farma Tbk’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PT Kalbe Farma Tbk have?
PT Kalbe Farma Tbk has 234,066,960 shares outstanding.
What happened to PT Kalbe Farma Tbk’s price movement after its last earnings report?
PT Kalbe Farma Tbk reported an EPS of $0.223 in its last earnings report. Following the earnings report the stock price went up 4.813%.
Which hedge fund is a major shareholder of PT Kalbe Farma Tbk?
Currently, no hedge funds are holding shares in PTKFY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PT Kalbe Farma Tbk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.97%
12-Months-Change
Fundamentals
Return on Equity
2.33%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PT Kalbe Farma Tbk
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors